Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets In Clopidogrel (Plavix(R)) Non-Responders
Medical News Today
13th November 2008
Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, announced new clinical data that demonstrate PRT060128, the Company's novel anti-platelet drug that directly and reversibly inhibits the P2Y12 ADP receptor, overcomes high platelet reactivity (HPR) in patients who do not respond to clopidogrel (Plavix(R)). The results [Abstract #5603] were presented at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans, LA.
13th November 2008
Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, announced new clinical data that demonstrate PRT060128, the Company's novel anti-platelet drug that directly and reversibly inhibits the P2Y12 ADP receptor, overcomes high platelet reactivity (HPR) in patients who do not respond to clopidogrel (Plavix(R)). The results [Abstract #5603] were presented at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans, LA.
Latest news:
3rd November 2009 -
Innovative Imaging System To Study Sudden Cardiac Arrest
3rd November 2009 -
Benefits Of Taking Part In Clinical Trials
30th October 2009 -
ESC Events In Asia Tackle Management Of Diabetes And Cardiovascular Disease
29th October 2009 -
Heart Patients Running The Red Light On Traffic Restrictions
29th October 2009 -
Onset Medical Performs First Human Use Of The SoloPath™ Endovascular Access Catheter To Deliver Percutaneous Aortic Heart Valve
29th October 2009 -
New CVD Guidelines And Position Papers
27th October 2009 -
Capsule Endoscopy Safe For Patients With Implantable Cardiac Devices
27th October 2009 -
Emory Program, Heart Attack, Myocardial Infarction, Cardiovascular Outcomes Research and Epidemiology
